Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10716317 | 0.90 | CETP (0.42) | CETPPKM | |
| SCHEMBL9170033 | 0.76 | GPR84 (0.45) | CETPTP53 | |
| SCHEMBL1350818 | 0.76 | GPR84 (0.45) | CETPTP53 | |
| SCHEMBL9175499 | 0.76 | GPR84 (0.45) | CETPTP53 | |
| SCHEMBL7856817 | 0.76 | CETP (0.39) | CETPPKM | |
| SCHEMBL9173507 | 0.76 | GPR84 (0.45) | CETPTP53 | |
| SCHEMBL7864974 | 0.76 | CETP (0.39) | CETPPKM | |
| SCHEMBL8532164 | 0.76 | GPR84 (0.45) | CETPTP53 | |
| SCHEMBL9177080 | 0.76 | GPR84 (0.45) | CETPTP53 | |
| SCHEMBL7865008 | 0.76 | CETP (0.39) | CETPPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7345174-B2 | Cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2008-03-18 | — | — | US | disclosed |
| US-7189867-B1 | Trifluoromethylcarbinol terminated thiols | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2007-03-13 | — | — | US | disclosed |
| US-20070010669-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, THE | 2007-01-11 | — | — | US | disclosed |
| US-20070010536-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010669-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | ACIN1, HDAC3, HDAC1 | CETP 2315/4885PKM 2254/4885TP53 88/4885 |
| US-20070010536-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | ACIN1, HDAC3, HDAC1 | CETP 2315/4885PKM 2254/4885TP53 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.